CTIS2023-507763-18-01
Active, not recruiting
Phase 1
Progesterone for prEventing Preterm births in women with PlacEnta pRevia (PEPPER-trial)
Amsterdam UMC0 sites142 target enrollmentOctober 26, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Placenta previa, preterm birth
- Sponsor
- Amsterdam UMC
- Enrollment
- 142
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women pregnant of a singleton – without any other high\-risk factor for preterm birth \- diagnosed with a placenta previa diagnosed between 18\- and 24 weeks of gestation.
Exclusion Criteria
- •1\. Multiple pregnancy, 2\. Major fetal congenital and/or chormosomal abnormalities, 3\. Cervical cerclage or pessary in situ or planned to be placed, 4\. Cervical dilation \= 3cm, 5\. Intra\-uterine fetal death, 6\. Women with an already existing indication for progesterone use per current guidelines, 7\. (Suspected) placenta accreta spectrum disorder, 8\. Contra\-indication for progesterone use, 9\. Inability to give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Progesterone at imminent premature birthProgesteron vid hotande förtidsbördIn this randomised, placebo-controlled pilot study the treatment group (n=30) will recieve a daily application of vaginal gel containing progesterone 90 mg/dose (Crinone, Seronomerck) until rupture of fetal membranes, partus or 34 gestational weeks. The control group (n=30) will recieve a daily application of vaginal gel (Replens, Campus Pharma), which is identical to Crinone except for progesterone hormone, until rupture of fetal membranes, partus or 34 gestational weeks.EUCTR2007-003348-31-SEDepartment of Woman and Child health, Karolinska University Hospital
Recruiting
Not Applicable
Quadruple-P follow-up<p>Women with short cervical length during mid-trimester, therefore having a highrer risk on preterm birth</p>NL-OMON26646one600
Completed
Phase 3
Pessary or Progesterone to Prevent Preterm delivery in women with short cervical length.preterm birth10028920NL-OMON50366Academisch Medisch Centrum960
Active, not recruiting
Phase 1
Pessary or Progesterone to Prevent Preterm delivery in women with short cervical lengthpreterm birthMedDRA version: 20.1Level: LLTClassification code 10023555Term: Labour prematureSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: LLTClassification code 10023545Term: Labor prematureSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.0Level: LLTClassification code 10036594Term: Premature birthSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: PTClassification code 10036600Term: Premature labourSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: LLTClassification code 10036599Term: Premature laborSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]EUCTR2013-002884-24-NLAMC960
Recruiting
Not Applicable
Pessary (cervical Ring) plus Progesterone to prevent Preterm deliveryRBR-3t8przIVERSIDADE ESTADUAL DE CAMPINAS